AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35924574 — intervention group
Group type: COMPARATOR
Intervention: Age ≥80 years
Number of subjects: 2403
Study 35924574 — intervention group
Group type: COMPARATOR
Intervention: Fewer fall risk factors
Number of subjects: 2403
Study 32273165 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-columnar bone grafts from the ramus
Number of subjects: 46
Study 32273165 — intervention group
Group type: COMPARATOR
Intervention: Rectangular bone grafts from the symphysis
Number of subjects: 46
Study 35492335 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide (500 mg, 3 times daily for 5 days)
Number of subjects: 498
Study 35492335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 498
Study 32443433 — intervention group
Group type: EXPERIMENTAL
Intervention: Three whole Zespri® SunGold kiwifruit including the skin for 4 weeks
Number of subjects: 38
Study 32443433 — intervention group
Group type: EXPERIMENTAL
Intervention: Three whole Zespri® SunGold kiwifruit without the skin for 4 weeks
Number of subjects: 38
Study 32443433 — intervention group
Group type: EXPERIMENTAL
Intervention: Three whole Zespri® SunGold kiwifruit (with or without skin)
Number of subjects: 38
Study 35167993 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP of 5 cmH2O until the end of mechanical ventilation
Number of subjects: 36
Study 35167993 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PEEP)
Number of subjects: 36
Study 35167993 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP group
Number of subjects: 36
Study 33798130 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase-only authentication using single-pixel optical imaging through scattering media.
Number of subjects: 0
Study 32845588 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Number of subjects: 2570
Study 32845588 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 2570
Study 32845588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2570
Study 35985028 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW) intervention
Number of subjects: 24
Study 35985028 — intervention group
Group type: EXPERIMENTAL
Intervention: CHW intervention
Number of subjects: 24
Study 33756503 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure (SBP) level 120-140 mm Hg
Number of subjects: 12820
Study 33756503 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure (SBP) level 120-140 mm Hg (Group M)
Number of subjects: 12820
Study 33756503 — intervention group
Group type: COMPARATOR
Intervention: Systolic Blood Pressure (SBP) levels <100 mm Hg, 100-120 mm Hg, and ≥140 mm Hg
Number of subjects: 12820
Study 32061140 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasally applied oxytocin (24 international units)
Number of subjects: 24
Study 32061140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 34728434 — intervention group
Group type: EXPERIMENTAL
Intervention: Suture button suspension (SBS)
Number of subjects: 76
Study 34728434 — intervention group
Group type: COMPARATOR
Intervention: Ligament reconstruction and tendon interposition (LRTI)
Number of subjects: 76
Study 34135449 — intervention group
Group type: EXPERIMENTAL
Intervention: Femtosecond-laser assisted cataract surgery (FLACS)
Number of subjects: 60
Study 34135449 — intervention group
Group type: COMPARATOR
Intervention: Phacoemulsification
Number of subjects: 60
Study 34135449 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher LOCS III cortical opacity quantifications
Number of subjects: 60
Study 34135449 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuclear opacities
Number of subjects: 60
Study 34135449 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline qAF
Number of subjects: 60
Study 32583975 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Oral Anticoagulants (DOAC)
Number of subjects: 84
Study 34997835 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-Dose Combination of Pitavastatin/Valsartan 4/160 mg
Number of subjects: 54
Study 34997835 — intervention group
Group type: COMPARATOR
Intervention: Individual components of Pitavastatin and Valsartan
Number of subjects: 54
Study 33164570 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 5103
Study 35620920 — intervention group
Group type: EXPERIMENTAL
Intervention: Twelve-session lifestyle intervention delivered by Promotoras in Spanish.
Number of subjects: 615
Study 35620920 — intervention group
Group type: COMPARATOR
Intervention: Six-session leadership training (control).
Number of subjects: 615
Study 33587674 — intervention group
Group type: EXPERIMENTAL
Intervention: LipiFlow treatment in LipiFlow-surgery eye
Number of subjects: 32
Study 33587674 — intervention group
Group type: EXPERIMENTAL
Intervention: LipiFlow treatment in LipiFlow-nonsurgery eye
Number of subjects: 32
Study 33587674 — intervention group
Group type: COMPARATOR
Intervention: LipiFlow-surgery eye
Number of subjects: 32
Study 33587674 — intervention group
Group type: COMPARATOR
Intervention: nonLipiFlow-surgery eye
Number of subjects: 32
Study 32604430 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy (30 minutes daily)
Number of subjects: 222
Study 32604430 — intervention group
Group type: COMPARATOR
Intervention: Control group (30 minutes of quiet time)
Number of subjects: 222
Study 1994041002 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 250 mg twice a day
Number of subjects: 54
Study 35383473 — intervention group
Group type: EXPERIMENTAL
Intervention: Family functioning improvement
Number of subjects: 203
Study 32745686 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonates
Number of subjects: 0
Study 32745686 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronate post hip fracture
Number of subjects: 0
Study 35358154 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-g bolus of tranexamic acid (TXA)
Number of subjects: 395
Study 35358154 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-g bolus plus 1-g infusion of tranexamic acid (TXA) over 8 hours
Number of subjects: 395
Study 35358154 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 395
Study 33629488 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical eflornithine cream twice daily for 16 weeks
Number of subjects: 40
Study 33629488 — intervention group
Group type: EXPERIMENTAL
Intervention: Long‐pulsed Nd‐YAG laser for 4 sessions at 4-week intervals
Number of subjects: 40
Study 33629488 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of topical eflornithine cream and long‐pulsed Nd‐YAG laser for 16 weeks
Number of subjects: 40
Study 33629488 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up after 12 weeks
Number of subjects: 40
Study 35533263 — intervention group
Group type: EXPERIMENTAL
Intervention: NIRIS classification
Number of subjects: 882
Study 35533263 — intervention group
Group type: EXPERIMENTAL
Intervention: Stockholm CT score
Number of subjects: 882
Study 35533263 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotterdam CT score
Number of subjects: 882
Study 35533263 — intervention group
Group type: EXPERIMENTAL
Intervention: Helsinki CT classification
Number of subjects: 882
Study 35533263 — intervention group
Group type: EXPERIMENTAL
Intervention: Marshall CT classification
Number of subjects: 882
Study 34188067 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT)
Number of subjects: 0
Study 34188067 — intervention group
Group type: COMPARATOR
Intervention: Control group (Prostate cancer‐free men from the general population)
Number of subjects: 0
Study 32135143 — intervention group
Group type: EXPERIMENTAL
Intervention: Expedited partner therapy prescription received
Number of subjects: 335
Study 32135143 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to dispense expedited partner therapy prescription
Number of subjects: 335
Study 32135143 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost of azithromycin 1000 mg for treatment of chlamydia
Number of subjects: 335
Study 32135143 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost of cefixime 400 mg for treatment of gonorrhea
Number of subjects: 335
Study 35102440 — intervention group
Group type: EXPERIMENTAL
Intervention: maxgraft®
Number of subjects: 36
Study 35102440 — intervention group
Group type: EXPERIMENTAL
Intervention: Puros®
Number of subjects: 36
Study 616774609 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal application of traditional Chinese medicine combined with chewing gum
Number of subjects: 108
Study 616774609 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment and nursing care (Control)
Number of subjects: 108
Study 35643684 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35641199 — intervention group
Group type: EXPERIMENTAL
Intervention: Well-formulated ketogenic diet (WFKD)
Number of subjects: 40
Study 35641199 — intervention group
Group type: COMPARATOR
Intervention: Mediterranean-plus diet (Med-Plus)
Number of subjects: 40
Study 35143661 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-lapse selection model for blastocyst transfer
Number of subjects: 776
Study 35143661 — intervention group
Group type: COMPARATOR
Intervention: Morphology alone for blastocyst transfer
Number of subjects: 776
Study 32543120 — intervention group
Group type: EXPERIMENTAL
Intervention: Edaravone 60 mg (therapeutic dose)
Number of subjects: 27
Study 32543120 — intervention group
Group type: EXPERIMENTAL
Intervention: Edaravone 300 mg (supratherapeutic dose)
Number of subjects: 27
Study 32543120 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 27
Study 32732587 — intervention group
Group type: EXPERIMENTAL
Intervention: Sliding hip screw
Number of subjects: 91
Study 32732587 — intervention group
Group type: COMPARATOR
Intervention: Cancellous screws
Number of subjects: 91
Study 32732587 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 4000 IU daily
Number of subjects: 91
Study 32732587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 34551207 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced sodium diet for 8 weeks
Number of subjects: 50
Study 34551207 — intervention group
Group type: COMPARATOR
Intervention: Usual sodium diet
Number of subjects: 50
Study 35618299 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical education intervention program (three 10-minute weekly medium- to high-intensity activities for one academic year)
Number of subjects: 295
Study 35618299 — intervention group
Group type: COMPARATOR
Intervention: Control group (treatment as usual)
Number of subjects: 295
Study 35618299 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical education intervention program
Number of subjects: 295
Study 33617910 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous Integrated Boost (SIB)
Number of subjects: 150
Study 33617910 — intervention group
Group type: COMPARATOR
Intervention: Sequential Boost (SEB)
Number of subjects: 150
Study 32730136 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological support based on positive suggestion (PSBPS)
Number of subjects: 20
Study 34923697 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital story (video-based approach)
Number of subjects: 20
Study 34923697 — intervention group
Group type: COMPARATOR
Intervention: Written brief (control group)
Number of subjects: 20
Study 33862265 — intervention group
Group type: EXPERIMENTAL
Intervention: FAE cycles with EF
Number of subjects: 1204
Study 33862265 — intervention group
Group type: COMPARATOR
Intervention: Controls (fresh autologous IVF cycles)
Number of subjects: 1204
Study 36175457 — intervention group
Group type: EXPERIMENTAL
Intervention: IRIS-enhanced VLE (IRIS-VLE)
Number of subjects: 133
Study 36175457 — intervention group
Group type: COMPARATOR
Intervention: Unenhanced VLE (VLE-IRIS)
Number of subjects: 133
Study 36175457 — intervention group
Group type: EXPERIMENTAL
Intervention: Unenhanced VLE (IRIS-VLE)
Number of subjects: 133
Study 35927580 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa (L-DOPA; 250 mg)
Number of subjects: 40
Study 35927580 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 32634344 — intervention group
Group type: EXPERIMENTAL
Intervention: Crohn's disease (CD)
Number of subjects: 302
Study 32634344 — intervention group
Group type: COMPARATOR
Intervention: Control group (without CD)
Number of subjects: 302
Study 32634344 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with PG and CD
Number of subjects: 302
Study 35459133 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to traumatic events in adulthood only
Number of subjects: 245
Study 35459133 — intervention group
Group type: EXPERIMENTAL
Intervention: No exposure to traumatic events
Number of subjects: 245
Study 35459133 — intervention group
Group type: EXPERIMENTAL
Intervention: Acting with awareness
Number of subjects: 245
Study 34810392 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF)
Number of subjects: 36
Study 34810392 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen
Number of subjects: 36
Study 34810392 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite
Number of subjects: 36
Study 34810392 — intervention group
Group type: COMPARATOR
Intervention: Periapical bleeding
Number of subjects: 36
Study 33215456 — intervention group
Group type: COMPARATOR
Intervention: 5-aminosalicylic acid (5-ASA)
Number of subjects: 46
Study 33215456 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (AZA)
Number of subjects: 46
Study 36484921 — intervention group
Group type: EXPERIMENTAL
Intervention: Shexiang Baoxin Pill combined with home‐based exercise training based on conventional drugs for 12 weeks
Number of subjects: 60
Study 36484921 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional drugs combined with home‐based exercise training for 12 weeks
Number of subjects: 60
Study 36484921 — intervention group
Group type: COMPARATOR
Intervention: Conventional drug treatment only
Number of subjects: 60
Study 33899331 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-infrared light (NIL) therapy combined with meibomian gland expression (MGX)
Number of subjects: 130
Study 33899331 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense pulsed light (IPL) therapy combined with meibomian gland expression (MGX)
Number of subjects: 130
Study 35445847 — intervention group
Group type: EXPERIMENTAL
Intervention: vonoprazan 10 mg every other day + clopidogrel 75 mg daily
Number of subjects: 12
Study 35445847 — intervention group
Group type: EXPERIMENTAL
Intervention: vonoprazan 10 mg daily + clopidogrel 75 mg daily
Number of subjects: 12
Study 35445847 — intervention group
Group type: COMPARATOR
Intervention: clopidogrel 75 mg daily
Number of subjects: 12
Study 35445847 — intervention group
Group type: EXPERIMENTAL
Intervention: vonoprazan 10 mg every other day
Number of subjects: 12
Study 35445847 — intervention group
Group type: EXPERIMENTAL
Intervention: vonoprazan 10 mg daily
Number of subjects: 12
Study 33646819 — intervention group
Group type: EXPERIMENTAL
Intervention: In-bore biopsy
Number of subjects: 286
Study 33421079 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy marketing strategies implemented in 16 intervention stores for 18 months, including increased availability of healthier 'target' products, prime shelf-placement, call-out promotion signs, and reduced availability of regular 'comparison' products.
Number of subjects: 33
Study 33421079 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy marketing strategies in intervention stores.
Number of subjects: 33
Study 33421079 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercept surveys with customers.
Number of subjects: 33
Study 33421079 — intervention group
Group type: EXPERIMENTAL
Intervention: Grocery marketing environment assessments in the same six food categories.
Number of subjects: 33
Study 34480785 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention group (frequent nutritional education at every outpatient visit)
Number of subjects: 96
Study 34480785 — intervention group
Group type: COMPARATOR
Intervention: Usual intervention group (nutritional education once a year)
Number of subjects: 96
Study 33223095 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 1778
Study 33223095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1778
Study 32324444 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-utterance condition
Number of subjects: 220
Study 32324444 — intervention group
Group type: COMPARATOR
Intervention: 50-utterance condition
Number of subjects: 220
Study 34727201 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine 1000 mg/day
Number of subjects: 62
Study 33248135 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate laser treatment
Number of subjects: 117
Study 33248135 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 117
Study 33382385 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine citrate disodium (DCD, 8.8 mg/day) + Vitamin D3 nasal drops (1.5x10^6 IU, once/week) for four weeks
Number of subjects: 60
Study 33382385 — intervention group
Group type: COMPARATOR
Intervention: Desloratadine citrate disodium (DCD, 8.8 mg/day)
Number of subjects: 60
Study 36031651 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital screening using a certified app on smartphones
Number of subjects: 5551
Study 36031651 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 5551
Study 33393042 — intervention group
Group type: EXPERIMENTAL
Intervention: Upfront CRS/HIPEC
Number of subjects: 148
Study 33393042 — intervention group
Group type: EXPERIMENTAL
Intervention: NACT + CRS/HIPEC
Number of subjects: 148
Study 33393042 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage CRS/HIPEC
Number of subjects: 148
Study 35022283 — intervention group
Group type: EXPERIMENTAL
Intervention: Wet-cupping therapy (hijama)
Number of subjects: 13
Study 35022283 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control group)
Number of subjects: 13
Study 34024878 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (statin group)
Number of subjects: 231
Study 34024878 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 231
Study 36284274 — intervention group
Group type: EXPERIMENTAL
Intervention: Journey of the Brave programme (intervention group, n=31)
Number of subjects: 90
Study 36284274 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=59)
Number of subjects: 90
Study 33547784 — intervention group
Group type: EXPERIMENTAL
Intervention: Atacicept 150 mg
Number of subjects: 253
Study 33547784 — intervention group
Group type: EXPERIMENTAL
Intervention: Atacicept 75 mg
Number of subjects: 253
Study 33547784 — intervention group
Group type: COMPARATOR
Intervention: Placebo/Atacicept 150 mg
Number of subjects: 253
Study 32045911 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering treatment
Number of subjects: 1000
Study 32045911 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure lowering treatment
Number of subjects: 1000
Study 35698748 — intervention group
Group type: EXPERIMENTAL
Intervention: Holistic birth support strategies
Number of subjects: 64
Study 34488034 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led systematic review of medications for PIM detection using explicit and implicit methods; communication of appropriate therapeutic strategies to physicians.
Number of subjects: 549
Study 34488034 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led systematic review of medications for PIM detection.
Number of subjects: 549
Study 34488034 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 549
Study 32517596 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended-learning course (5 hours of e-learning and 16 hours of near-peer tutoring)
Number of subjects: 152
Study 32517596 — intervention group
Group type: COMPARATOR
Intervention: Faculty-led 2.5-day ultrasound course
Number of subjects: 152
Study 35983513 — intervention group
Group type: EXPERIMENTAL
Intervention: Online prediction model for primary aldosteronism (PA)
Number of subjects: 1314
Study 34410617 — intervention group
Group type: EXPERIMENTAL
Intervention: Effort condition (Try Hard instructions)
Number of subjects: 0
Study 34410617 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no Try Hard instructions)
Number of subjects: 0
Study 34225463 — intervention group
Group type: EXPERIMENTAL
Intervention: Core formulation regimen (test group)
Number of subjects: 100
Study 34225463 — intervention group
Group type: COMPARATOR
Intervention: Non-compliant group (control group)
Number of subjects: 100
Study 32247311 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-initiated Kangaroo Mother Care (ciKMC)
Number of subjects: 552
Study 32247311 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 552
Study 32247311 — intervention group
Group type: EXPERIMENTAL
Intervention: ciKMC
Number of subjects: 552
Study 35385591 — intervention group
Group type: EXPERIMENTAL
Intervention: Small text warnings
Number of subjects: 1360
Study 35385591 — intervention group
Group type: EXPERIMENTAL
Intervention: Large text warnings
Number of subjects: 1360
Study 35385591 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial (image-and-text) warnings
Number of subjects: 1360
Study 35385591 — intervention group
Group type: COMPARATOR
Intervention: Control (no warnings)
Number of subjects: 1360
Study 32529563 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback
Number of subjects: 22
Study 32529563 — intervention group
Group type: COMPARATOR
Intervention: Electrical stimulation
Number of subjects: 22
Study 32529563 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 22
Study 33236329 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO) in combination with conventional induction chemotherapy
Number of subjects: 1000000
Study 33236329 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO) as monotherapy for newly diagnosed AML
Number of subjects: 1000000
Study 33236329 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO) as monotherapy for R/R AML
Number of subjects: 1000000
Study 33090597 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Restricted (5 hours per night)
Number of subjects: 31
Study 33090597 — intervention group
Group type: COMPARATOR
Intervention: Well Rested (8 hours per night)
Number of subjects: 31
Study 33090597 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions (SR and WR)
Number of subjects: 31